Flexion Therapeutics’ Zilretta pain drug proves effective in the third phase clinical trial, prompting the company’s shares to jump. Following the Tuesday announcement, Flexion Therapeutics shares rose by 38 percent in extended trading. Zilretta, the company’s pain relief drug offered to knee osteoarthritis patients has proved largely successful during Phase III of the … [Read more...]